Amneal Pharmaceuticals Received Its First Product Approval In China. Sevelamer Carbonate Was Approved And Is Expected To Launch Shortly. In Addition, The Company Expects To Launch Oseltamivir Phosphate In China This Year As Well, Upon Approval
Portfolio Pulse from Benzinga Newsdesk
Amneal Pharmaceuticals has received approval for its first product, Sevelamer Carbonate, in China and expects to launch it soon. The company also plans to launch Oseltamivir Phosphate in China this year, pending approval. Amneal has six more products under review in China and plans to register more over time. Since 2019, Amneal has been collaborating with Fosun Pharmaceuticals to bring key therapies to market in China.
September 06, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amneal Pharmaceuticals has received its first product approval in China, which could potentially open up a new market for the company. The collaboration with Fosun Pharmaceuticals could further strengthen its position in the Chinese market.
The approval of Amneal's first product in China represents a significant milestone for the company as it opens up a new market. The ongoing collaboration with Fosun Pharmaceuticals could help Amneal establish a strong presence in the Chinese market, which could potentially boost its revenues and profitability in the long run.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100